Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.69 |
| ▸ | KDM1A | O60341 | 3/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MGAM | O43451 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SI | P14410 | 1/20 | 0.60 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14983946 | 1.00 | NOX4 (0.69) | NOX4KDM1AMAOAMAOBNPC1 | |
| SCHEMBL6749927 | 1.00 | NOX4 (0.69) | NOX4KDM1AMAOAMAOBNPC1 | |
| SCHEMBL19283308 | 0.90 | KDM1A (0.78) | NOX4KDM1AMAOAMAOBNPC1 | |
| SCHEMBL19283307 | 0.90 | KDM1A (0.78) | NOX4KDM1AMAOAMAOBNPC1 | |
| Salicylaldehyde Benzoyl Hydrazone SCHEMBL414978 | 0.89 | KDM1A (0.82) | KDM1AMAOAMAOBNPC1HTT | |
| Salicylaldehyde Benzoyl Hydrazone SCHEMBL30193248 | 0.89 | KDM1A (0.82) | KDM1AMAOAMAOBNPC1HTT | |
| Salicylaldehyde Benzoyl Hydrazone SCHEMBL6638532 | 0.89 | KDM1A (0.82) | KDM1AMAOAMAOBNPC1HTT | |
| Salicylaldehyde Benzoyl Hydrazone SCHEMBL414977 | 0.89 | KDM1A (0.82) | KDM1AMAOAMAOBNPC1HTT | |
| SCHEMBL6568245 | 0.88 | MAPT (0.74) | MAPTNTRK1 | |
| SCHEMBL14223790 | 0.88 | MAPT (0.74) | MAPTNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110963-A1 | Novel hydrazones | ARPIDA AG (CH) | 2004-06-10 | — | — | US | claimed |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
| US-20040110963-A1 | Novel hydrazones | ARPIDA AG (CH) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | GRIN2A, GRIN3A, GRIN1 | NOX4 3254/4885KDM1A 1716/4885MAOA 1460/4885 |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | GRIN2A, GRIN3A, GRIN1 | NOX4 3254/4885KDM1A 1716/4885MAOA 1460/4885 |
| US-20040110963-A1 | Novel hydrazones | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO | NOX4 466/4885KDM1A 2684/4885MAOA 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.